Overview

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Status:
Completed

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the long-term safety of recombinant human Factor VIII Fc fusion protein (rFVIIIFc) in participants with hemophilia A. The secondary objective of the study is to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in participants with hemophilia A.

Phase:

Phase 3

Details

Lead Sponsor:

Biogen
Bioverativ Therapeutics Inc.

Treatments:

Factor VIII